Sign in

Mechthild Krause, Prof.

@mekrause.bsky.social
98 followers 87 following 31 posts

Radiation Oncologist, Director #OncoRay, RadOnc University Hospital Dresden. Past-President #DEGRO. #radiationoncology; #radiotherapy; #HZDR; #DKTK; #NCT; #RadOnc Posts are my own

PostsRepliesMedia
Mechthild Krause, Prof. @mekrause.bsky.social · 15/06/2026
@ESTRO target volume guidelines for locoregional breast cancer radiotherapy prospectively validated within Skagen I trial. Congratulations to this important work @au.dk #radiotherapy #radiooncology www.sciencedirect.com/science/arti...
sciencedirect.com
Validation of the ESTRO target volume consensus guideline for early-stage breast cancer in the DBCG Skagen Trial 1
Adjuvant loco-regional radiotherapy reduces recurrence risk and enhances survival in early-stage breast cancer. The ESTRO consensus guideline on targe…
010
Mechthild Krause, Prof. @mekrause.bsky.social · 26/05/2026
ESTRO breast cancer target volume guideline prospectively validated within Skagen I trial. Nearly all recurrences within the proposed CTV´s. Congratulations to this important work! #radiotherapy @au.dk @estroradiotherapy.bsky.social www.sciencedirect.com/science/arti...
sciencedirect.com
Validation of the ESTRO target volume consensus guideline for early-stage breast cancer in the DBCG Skagen Trial 1
Adjuvant loco-regional radiotherapy reduces recurrence risk and enhances survival in early-stage breast cancer. The ESTRO consensus guideline on targe…
010
Reposted by Mechthild Krause, Prof.
European Organisation for Research and Treatment of Cancer @eortc.org · 17/05/2026
📢Final EORTC 22922/10925 trial results presented at #ESTRO26 20‑year data shows lymph node RT lowers breast cancer mortality but not overall survival, highlighting the need for very long‑term follow‑up. 👉 www.eortc.org/blog/2026/05/17/final…
012
Reposted by Mechthild Krause, Prof.
European Society for Radiotherapy and Oncology (ESTRO) @estroradiotherapy.bsky.social · 16/05/2026
📢Blood test that detects tumour DNA could help guide treatment when cancer has spread Read the press release: bit.ly/4fnB5DN
021
Mechthild Krause, Prof. @mekrause.bsky.social · 16/05/2026
Very good to have so many active RTTs at the #ESTRO2026. Important topic #radiotherapy; #radiationoncology
020
Mechthild Krause, Prof. @mekrause.bsky.social · 16/05/2026
Thomas Bortfeld received the Breur Award today. Congratulations! #ESTRO2026; #radiotherapy; #radiationoncology
010
Mechthild Krause, Prof. @mekrause.bsky.social · 16/05/2026
Congratulations to Daniel Zips receiving the Regaud award today. #ESTRO2026; #radiotherapy; #radiationoncology
010
Reposted by Mechthild Krause, Prof.
Deutsches Krebsforschungszentrum (DKFZ) @dkfz.bsky.social · 27/03/2026
Dreaming of a career in cancer research? Join the International PhD Program at DKFZ - Germany’s largest biomedical research center. Explore #cancerresearch including #cancerbiology, #bioinformatics, #epidemiology & #medicalphysics. The Summer Selection is open now 👉 apply here: t1p.de/hl56b
11111
Mechthild Krause, Prof. @mekrause.bsky.social · 24/03/2026
Danke and die Kolleg:innen! Sehr wichtig für unsere Kinder mit Krebserkrankungen
020
Mechthild Krause, Prof. @mekrause.bsky.social · 14/02/2026
Validation of a DNA methylation classifier hypoxia-M as prognosticator for patients with postoperative radiochemotherapy in head and neck cancer. @dkfz.bsky.social #radonc www.sciencedirect.com/science/arti...
sciencedirect.com
A tumor DNA-Methylome derived signature of Hypoxia Identifies HPV-negative head and neck cancer patients at risk for distant metastasis after postoperative radiochemotherapy (PORT-C)
Tumor hypoxia is a predictive biomarker of treatment resistance in patients with head and neck squamous cell carcinoma (HNSCC). We previously reported…
010
Mechthild Krause, Prof. @mekrause.bsky.social · 14/11/2025
Another dataset on the potential of xenografts as valuable models for the development of biomarkers for individualized radiotherapy - along with the robustness of biomarkers predicting local control in xenografts (IR+Cetux) and in patients (radiochemo). www.sciencedirect.com/science/arti...
sciencedirect.com
Application of a preclinical 18-gene classifier to patients with locally advanced HNSCC
In a previous preclinical trial on human HNSCC xenografts, 18 genes were predictive for adding cetuximab to fractionated radiotherapy. Here, we apply …
020
Mechthild Krause, Prof. @mekrause.bsky.social · 14/11/2025
In pediatric diffuse midline glioma/diffuse intrinsic pontine glioma, craniospinal spread is a frequent cause of death. Here, safety of combining craniospinal irradiation with temozolomide is shown, informing future clinical trial design (e.g., SIOPE HGG-01). www.sciencedirect.com/science/arti...
sciencedirect.com
Haematotoxicity of Craniospinal Radiochemotherapy for Metastatic Paediatric High-Grade Glioma
Paediatric high-grade gliomas (pedHGGs) have a dismal prognosis, often characterised by early and diffuse disease progression. Novel treatment approac…
020
Mechthild Krause, Prof. @mekrause.bsky.social · 14/11/2025
Independent validation of NTCP models for predicting radiation induced contrast enhancements after proton therapy - increased periventricular radiosensitivity. Variable RBE clinically relevant, consideration will further improve safety of proton radiotherapy. www.sciencedirect.com/science/arti...
sciencedirect.com
Model validation confirms variable relative biological effectiveness and elevated periventricular sensitivity after proton therapy of brain tumors
This study validates recently proposed voxel-wise and patient-wise predictive models for localization and occurrence of late radiation-induced contras…
010
Mechthild Krause, Prof. @mekrause.bsky.social · 30/09/2025
Read the paper on radiotherapy with immun checkpoint and TK inhibitors - ESTRO/ESMO consensus about risks of combination www.sciencedirect.com/science/arti...
sciencedirect.com
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors
The combination of radiotherapy (RT) with targeted agents or immunotherapy may result in improved outcomes, but it can also increase toxicity. However…
020
Reposted by Mechthild Krause, Prof.
Deutsche Forschungsgemeinschaft @dfg.de · 03/09/2025
#WissenschaftlicheIntegritaet: Die Leitlinie 14 des Kodex beschäftigt sich mit der #Autorschaft: Wann gilt man als Autor*in einer Arbeit? Was ist ein genuiner Beitrag? Was muss bei einer Publikation mit Blick auf die #GWP beachtet werden? 1/3
1134
Mechthild Krause, Prof. @mekrause.bsky.social · 23/08/2025
Wissenschaft für Demokratie – Wir für Dich e.V. – ist für den Progressive Voices Award 2025 nominiert worden! 🎉. Stimmt ab, Ihr habt 5 Stimmen, auch in den anderen Kategorien für tolle Initiativen Abstimmung: brandnewbundestag.de/progressive-... Teilen ausdrücklich erwünscht! 💜
brandnewbundestag.de
Progressive Voices Award 2025 - Brand New Bundestag
Bereits das dritte Jahr in Folge lenken wir den Blick bewusst auf das Mutmachende in Politik und Gesellschaft und verleihen den Progressive Voices Award 2025.
030
Reposted by Mechthild Krause, Prof.
Kulturbüro Sachsen @kbsachsen.bsky.social · 23/07/2025
💪 Selbstwirksam aktiv gegen #RechteRaumnahme durch #Reichsbürger ! Unser Beratungsfall aus #Halsbrücke #Sachsen ist ein schönes Beispiel dafür, wie zivilgesellschaftliches Engagement gg #Rechtsextremismus in langfristiges, konstruktives Engagement für #Demokratie münden kann.
Aus der Praxis des Kulturbüro Sachsen: Halsbrücke. Wie sich Berger*innen gegen die Ansiedlung von Reichsbürger*innen wehren können. Motiv: Brücke in Halsbrücke
16919
Mechthild Krause, Prof. @mekrause.bsky.social · 07/07/2025
After brain irradiation, microglia density increases with dose, more in the periventricular region. Correlation with contrast enhancementin MRI -- potential mechanism of brain necrosis. #RadOnc @hzdr.bsky.social @oncoalert.bsky.social www.ctro.science/article/S240...
ctro.science
Cell-specific analysis of microglia following partial brain proton irradiation in mice
In recent years, proton therapy has been established as a curative treatment for pediatric brain tumors and has demonstrated significant potential for adult brain tumors [1,2]. The advantage of proton...
040
Mechthild Krause, Prof. @mekrause.bsky.social · 21/06/2025
Zum ersten Mal hybrid Fortbildung für Patientenvertreter und Interessierte auf dem #DEGRO Kongress. Danke den ca 80 Teilnehmer:innen, davon 40 vor Ort. Und den Mitorganisatoren. @dkfz.bsky.social
121
Mechthild Krause, Prof. @mekrause.bsky.social · 21/06/2025
Danke an die co-Kongresspräsidentinnen Esther Troost und Andrea Wittig und die Kongress- Koordinatorin Katja Storch #DEGRO
110
Mechthild Krause, Prof. @mekrause.bsky.social · 21/06/2025
Der #DEGRO Kongress geht heute zuende. Sehr spannende Sitzung: was können wir eigentlich aus welchen Studien schlussfolgern?
000
Mechthild Krause, Prof. @mekrause.bsky.social · 05/05/2025
Vienna outside of the conference Center 😊 #ESTRO25
130
Mechthild Krause, Prof. @mekrause.bsky.social · 05/05/2025
Two of the talks in the best papers session came from Dresden. Congratulations Martina Palkowitsch, PhD student, and Annett Linge, clinician scientist. #ESTRO25 #radonc
040
Reposted by Mechthild Krause, Prof.
Ane Appelt @cancerphysicist.bsky.social · 04/05/2025
I’m SO delighted to finally see first STAR-TREC data reported 🤩 #ESTRO25 Short course RT vs chemorad for organ preservation in early stage rectal cancer 61% vs 80% TME-free survival at 12 months ➡️ More organ preservation with long-course chemorad! #radonc #rectalcancer
172
Reposted by Mechthild Krause, Prof.
hannaradonc.bsky.social @hannaradonc.bsky.social · 03/05/2025
oncodaily.com/societies/hy...
oncodaily.com
HYPO-RT-PC Phase III trial: Two-Week Radiotherapy Proven as Safe and Effective as Eight-Week Course for Prostate Cancer, After 10-Year Follow-Up - OncoDaily
HYPO-RT-PC trial shows that ultra-hypofractionated radiotherapy is as effective and safe as 8-weektx for localized prostate cancer
001
Reposted by Mechthild Krause, Prof.
The New York Times @nytimes.com · 02/05/2025
Robert F. Kennedy Jr. will direct federal health agencies to explore potential new treatments for measles as the U.S. faces its largest outbreak in 25 years. Experts fear the decision could have grave consequences, as studies show the existing vaccine is 97% effective in preventing infection.
nytimes.com
RFK Jr. Orders Search for New Measles Treatments Instead of Urging Vaccination
Decades of research have turned up no miracle treatment for measles, but studies show the M.M.R. shot is 97 percent effective in preventing the disease.
217581812677
Mechthild Krause, Prof. @mekrause.bsky.social · 03/05/2025
Congratulations Michael Baumann @dkfz.bsky.social to the Jens Overgaard Legacy Award #ESTRO25 #RadOnc
171
Mechthild Krause, Prof. @mekrause.bsky.social · 03/05/2025
Birgitte Offersen showing the results of Skagen1 trial - hypofx vs conventional RT in high risk breast cancer patients with indication for lymphnode irradiation. Same side effects, same local control but worse survival. Due to lower RT dose? #ESTRO25 #RadOnk
011
Mechthild Krause, Prof. @mekrause.bsky.social · 02/05/2025
At Sep 7th 1953 the first patient hast received radiotherapy with a linear accelerator. Sept 7th, 2025 will be the world radiotherapy awareness day. Safe and effektive treatment to cure cancer. Equal access worldwide still a problem.
100
Mechthild Krause, Prof. @mekrause.bsky.social · 30/04/2025
www.degro-kongress.org DEGRO-Kongress, 19.-21.06.2025 in der Messe Dresden. Hochwertige Wissenschaft + schöne Stadt. Sehr viele haben sich schon angemeldet - Sie auch? Patienten unten weiterlesen
degro-kongress.org
DEGRO 2025 – Radioonkologie [Teamwork] Maßgeschneidert. Patientenzentriert. Zukunftsorientiert. Selbstbestimmt im Team
Der 31. Kongress der Deutschen Gesellschaft für Radioonkologie findet vom 19. bis 21. Juni 2025 in Dresden statt.
100
Mechthild Krause, Prof. @mekrause.bsky.social · 23/04/2025
Great and much needed trial, looking forward the tumor outcome
010
Reposted by Mechthild Krause, Prof.
IJROBP @ijrobp.bsky.social · 14/04/2025
RACE-GB, the first ever phase 3 randomized study showing overall survival improvement from chemotherapy combined with #radiation for gallbladder cancer. Article: www.redjournal.org/article/S036... Podcast: www.redjournal.org/audio-do/red...
redjournal.org
A Randomized Study of Consolidation Chemoradiotherapy Versus Observation After First-line Chemotherapy in Advanced Gallbladder Cancers: RACE-GB study
Chemotherapy (CT) is the standard of care for patients presenting with unresectable advanced gallbladder carcinoma (GBC) but their prognosis remains poor. The value of consolidation CT and radiation t...
042
Reposted by Mechthild Krause, Prof.
NEJM.org @nejm.org · 23/03/2025
The INSEMA trial involving patients with clinically node-negative, T1 breast cancer showed that the omission of axillary surgery was noninferior to sentinel-lymph-node biopsy. Full trial results and Research Summary: nej.md/41o5L0Z #MedSky #Oncology
The New England Journal of Medicine 
Axillary Surgery in Breast Cancer 
A Research Summary based on Reimer T et al. | 10.1056/NEJMoa2412063 | Published on December 12, 2024  

Visual representations of the patients in the trial and the treatments they were assigned.     

Read the full Research Summary at NEJM.org.
0164
Reposted by Mechthild Krause, Prof.
IJROBP @ijrobp.bsky.social · 21/03/2025
The bird people seemed very excited about this study. #IJROBP #radonc www.redjournal.org/article/S036...
redjournal.org
Boswellia Serrata for Cerebral Radiation Necrosis After Radiosurgery for Brain Metastases
Radiation necrosis (RN) is a dose-limiting toxicity of stereotactic radiosurgery (SRS) for brain metastases. Oral corticosteroids are not optimal for long-term management, given multiple side effects....
011
Reposted by Mechthild Krause, Prof.
Helmholtz-Gemeinschaft @helmholtz.de · 21/02/2025
Wir unterstützen die Kampagne #Zusammenland für Demokratie, Zusammenhalt, Weltoffenheit und Respekt!
Grafik mit Text: Gemeinsam sind wir stärker. #Zusammenland
04110
Reposted by Mechthild Krause, Prof.
Alexandra Witze @alexwitze.bsky.social · 18/02/2025
This morning, the US National Science Foundation fired 168 employees, approximately 10% of its workforce, for no cause other than they were the agency's most recent hires. 🧪 Co-workers are leaving supportive messages before they have to clear out of the building at 5 p.m. Sent to me by a source ⬇️
Handwritten notes on a metal table at the National Science Foundation, 2/18/25. The messages include "You deserve better! Thank you!"; "Thank you colleagues! This RIF is WRONG. These orders are immoral & illegal"; and "Your service will forever be remembered and deeply valued - ENG directorate".
191358487
Reposted by Mechthild Krause, Prof.
Ananya Choudhury @achoud72.bsky.social · 10/02/2025
👀 Take a look - we're on the hunt for a #postdoc to join us. Interested in innovative 3D models for translational research? @official-uom.bsky.social @mcrcnews.bsky.social @profajchalmers.bsky.social www.jobs.manchester.ac.uk/internal/Job...
jobs.manchester.ac.uk
Research Associate in Biomaterials:University campus and The Christie NHS Foundation Trust site, Withington, Manchester
033
Reposted by Mechthild Krause, Prof.
Catharine Clark @catharineclark.bsky.social · 13/02/2025
🚀 Save the Date! The 8th ESTRO Physics Workshop: Science in Development is coming! 📍 Toulouse, France 📅 23 – 24 October 2025 Two days of dynamic discussions, collaboration, and innovation in radiation oncology physics! Stay tuned for more details on the programme! bit.ly/3X0Jcw5
bit.ly
ESTRO Physics Workshop 2025 - Science in Development
033
Reposted by Mechthild Krause, Prof.
Nature Cancer @natcancer.nature.com · 12/02/2025
📢Check out this Research Article by Jens Kleesiek, Martin Schuler, Frederick Klauschen and colleagues @naturecancer.bsky.social 'Decoding #pancancer treatment outcomes using #multimodal real-world data and explainable #artificialintelligence' 🔗 www.nature.com/articles/s43...
nature.com
Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence - Nature Cancer
Keyl et al. present an explainable artificial intelligence model-based real-world data analysis from over 15,000 patients across 38 cancer types, identified key prognostic marker interactions, and con...
082
Reposted by Mechthild Krause, Prof.
Icro Meattini @icromeattini.bsky.social · 09/02/2025
Long-Term Outcomes of #Radiation Monotherapy Versus Combined RT + Hormone Therapy in Low-Risk Early-Stage #BreastCancer Patients 70 Years or Older After Breast-Conserving Surgery @oncoalert.bsky.social #OncoAlert @ijrobp.bsky.social #radonc www.redjournal.org/article/S036...
redjournal.org
Long-Term Outcomes of Radiation Monotherapy Versus Combined Radiation Monotherapy + Hormone Therapy in Low-Risk Early-Stage Breast Cancer Patients 70 Years or Older After Breast-Conserving Surgery
Standard therapy for breast cancer after breast-conserving surgery is radiation therapy (RT) plus hormone therapy (HT). For patients with a low-risk of recurrence, there is an interest in deescalating...
075
Reposted by Mechthild Krause, Prof.
Yüksel Ürün @yukselurun.bsky.social · 07/02/2025
Largest AI Mammography Trial: Game-Changer! 🔍 105,934 women screened ↗️ 29% more cancers detected ↘️ 44% reduction in screen-reading workload ✅ No rise in false positives AI is reshaping breast cancer screening! #BreastCancer #AI #Oncology #Cancer @oncoalert.bsky.social @oncbrothers.bsky.social
033
Reposted by Mechthild Krause, Prof.
HZDR @hzdr.bsky.social · 04/02/2025
Über unseren #Technologietransfer fördern wir Ideen, die das Potenzial haben, den Sprung aus dem Labor in die industrielle Anwendung zu schaffen. Erfolgreiche Transferprojekte können Besucher*innen des #HZDR in einer neuen Ausstellung am Standort Rossendorf entdecken. www.hzdr.de/presse/trans...
Verschiedene Exponate der Transferausstellung "Von der Forschung in die Anwendung" mit Mehrphasenmesstechnik der HZDR Innovation im Vordergrund.
111
Reposted by Mechthild Krause, Prof.
Cancer Research UK Manchester Institute @cruk-mi.bsky.social · 30/01/2025
*NEW* Review from Prof Rob Bristow's lab on the relationship between #hypoxia in tumours, genomic instability and tumour #evolution "Possible ways to counter the effects of hypoxia to block tumour evolution and improve treatment outcomes are described." @mcrcnews.bsky.social @cancerresearchuk.org
074
Mechthild Krause, Prof. @mekrause.bsky.social · 30/01/2025
Higher NTCP with variable RBE predictions in Proton RT of brain tumours- especially for blindness and deppendent in Patient factors. LET or track-end optimization can lower the risk. @hzdr.bsky.social @oncoalert.bsky.social www.sciencedirect.com/science/arti...
sciencedirect.com
Variable-RBE-induced NTCP predictions for various side-effects following proton therapy for brain tumors – Identification of high-risk patients and risk mitigation
Disregarding the increase of relative biological effectiveness (RBE) may raise the risk of acute and late adverse events after proton beam therapy (PB…
054
Reposted by Mechthild Krause, Prof.
Henning Willers, MD, FASTRO @henningwillersmd.bsky.social · 29/01/2025
📢Thrilled to have started again our Annual Radiation Biology Lecture Series with robust attendance & all the radiation chemistry effects you need to know to understand #radiotherapy😊 ☢️🔬👩‍🔬 @massgeneralbrigham.bsky.social @harvard.edu @oncoalert.bsky.social #radbio
052